Which has stronger earnings and valuation, TRVI or BLTE?

Belite Bio is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trevi Therapeutics N/A N/A -$42.76M -$0.34 N/A Belite Bio N/A N/A -$77.61M -$2.73 N/A

Is TRVI or BLTE more profitable?

Belite Bio's return on equity of -11.84% beat Trevi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Trevi Therapeutics N/A -23.59% -22.64% Belite Bio N/A -11.84% -11.62%

Does the media favor TRVI or BLTE?

In the previous week, Trevi Therapeutics had 4 more articles in the media than Belite Bio. MarketBeat recorded 6 mentions for Trevi Therapeutics and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.88 beat Trevi Therapeutics' score of 0.81 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LQDA or TRVI?

In the previous week, Liquidia had 6 more articles in the media than Trevi Therapeutics. MarketBeat recorded 12 mentions for Liquidia and 6 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.81 beat Liquidia's score of 0.72 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TRVI or AMRX?

In the previous week, Amneal Pharmaceuticals had 5 more articles in the media than Trevi Therapeutics. MarketBeat recorded 11 mentions for Amneal Pharmaceuticals and 6 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.81 beat Amneal Pharmaceuticals' score of 0.54 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, TRVI or DFTX?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trevi Therapeutics N/A N/A -$42.76M -$0.34 N/A Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A

Is TRVI or DFTX more profitable?

Trevi Therapeutics' return on equity of -23.59% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Trevi Therapeutics N/A -23.59% -22.64% Definium Therapeutics N/A -84.01% -63.66%

Does the media favor TRVI or DFTX?

In the previous week, Definium Therapeutics had 39 more articles in the media than Trevi Therapeutics. MarketBeat recorded 45 mentions for Definium Therapeutics and 6 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.81 beat Definium Therapeutics' score of 0.33 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Definium Therapeutics 8 Very Positive mention(s) 11 Positive mention(s) 12 Neutral mention(s) 5 Negative mention(s) 5 Very Negative mention(s) Neutral

Trevi Therapeutics (TRVI) Competitors

$14.95 -0.26 (-1.71%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$14.96 +0.01 (+0.07%)

As of 09/18/2026 07:30 PM Eastern

Compare

TRVI vs. BLTE, LNTH, LQDA, AMRX, and DFTX

Should you buy Trevi Therapeutics stock or one of its competitors? Trevi Therapeutics's main competitors and comparable companies include Belite Bio (BLTE), Lantheus (LNTH), Liquidia (LQDA), Amneal Pharmaceuticals (AMRX), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Trevi Therapeutics compare to Belite Bio?

Trevi Therapeutics (NASDAQ:TRVI) and Belite Bio (NASDAQ:BLTE) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

Belite Bio's return on equity of -11.84% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.59%	-22.64%
Belite Bio	N/A	-11.84%	-11.62%

Trevi Therapeutics presently has a consensus price target of $27.08, suggesting a potential upside of 81.16%. Belite Bio has a consensus price target of $218.73, suggesting a potential upside of 27.94%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Trevi Therapeutics is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Belite Bio is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 15.4% of Trevi Therapeutics shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Trevi Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, indicating that its share price is 223% less volatile than the broader market.

In the previous week, Trevi Therapeutics had 4 more articles in the media than Belite Bio. MarketBeat recorded 6 mentions for Trevi Therapeutics and 2 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.88 beat Trevi Therapeutics' score of 0.81 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Trevi Therapeutics beats Belite Bio on 11 of the 14 factors compared between the two stocks.

How does Trevi Therapeutics compare to Lantheus?

Trevi Therapeutics (NASDAQ:TRVI) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Trevi Therapeutics currently has a consensus target price of $27.08, suggesting a potential upside of 81.16%. Lantheus has a consensus target price of $108.11, suggesting a potential upside of 7.52%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Trevi Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

Lantheus has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A
Lantheus	$1.56B	4.22	$233.56M	$4.14	24.29

Lantheus has a net margin of 17.69% compared to Trevi Therapeutics' net margin of 0.00%. Lantheus' return on equity of 28.10% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.59%	-22.64%
Lantheus	17.69%	28.10%	14.35%

Trevi Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market.

In the previous week, Trevi Therapeutics had 6 more articles in the media than Lantheus. MarketBeat recorded 6 mentions for Trevi Therapeutics and 0 mentions for Lantheus. Lantheus' average media sentiment score of 1.73 beat Trevi Therapeutics' score of 0.81 indicating that Lantheus is being referred to more favorably in the news media.

Company	Overall Sentiment
Trevi Therapeutics	Positive
Lantheus	Very Positive

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 15.4% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Lantheus beats Trevi Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Trevi Therapeutics compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Trevi Therapeutics (NASDAQ:TRVI) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Liquidia presently has a consensus price target of $98.08, indicating a potential upside of 46.66%. Trevi Therapeutics has a consensus price target of $27.08, indicating a potential upside of 81.16%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Trevi Therapeutics is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 25.6% of Liquidia shares are owned by company insiders. Comparatively, 15.4% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Trevi Therapeutics has lower revenue, but higher earnings than Liquidia. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	37.81	-$68.92M	$1.37	48.82
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A

In the previous week, Liquidia had 6 more articles in the media than Trevi Therapeutics. MarketBeat recorded 12 mentions for Liquidia and 6 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.81 beat Liquidia's score of 0.72 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trevi Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Liquidia has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Liquidia has a net margin of 30.74% compared to Trevi Therapeutics' net margin of 0.00%. Liquidia's return on equity of 149.65% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Trevi Therapeutics	N/A	-23.59%	-22.64%

Summary

Liquidia and Trevi Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Trevi Therapeutics compare to Amneal Pharmaceuticals?

Trevi Therapeutics (NASDAQ:TRVI) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

In the previous week, Amneal Pharmaceuticals had 5 more articles in the media than Trevi Therapeutics. MarketBeat recorded 11 mentions for Amneal Pharmaceuticals and 6 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.81 beat Amneal Pharmaceuticals' score of 0.54 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Trevi Therapeutics presently has a consensus price target of $27.08, indicating a potential upside of 81.16%. Amneal Pharmaceuticals has a consensus price target of $20.14, indicating a potential upside of 7.66%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Trevi Therapeutics is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Trevi Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 15.4% of Trevi Therapeutics shares are owned by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Amneal Pharmaceuticals has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A
Amneal Pharmaceuticals	$3.12B	1.92	$72.06M	$0.49	38.18

Amneal Pharmaceuticals has a net margin of 5.05% compared to Trevi Therapeutics' net margin of 0.00%. Trevi Therapeutics' return on equity of -23.59% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.59%	-22.64%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Summary

Amneal Pharmaceuticals beats Trevi Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Trevi Therapeutics compare to Definium Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Definium Therapeutics (NASDAQ:DFTX) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Trevi Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market.

In the previous week, Definium Therapeutics had 39 more articles in the media than Trevi Therapeutics. MarketBeat recorded 45 mentions for Definium Therapeutics and 6 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.81 beat Definium Therapeutics' score of 0.33 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Definium Therapeutics	8 Very Positive mention(s)	11 Positive mention(s)	12 Neutral mention(s)	5 Negative mention(s)	5 Very Negative mention(s)	Neutral

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are owned by institutional investors. 15.4% of Trevi Therapeutics shares are owned by insiders. Comparatively, 2.4% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Trevi Therapeutics' return on equity of -23.59% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.59%	-22.64%
Definium Therapeutics	N/A	-84.01%	-63.66%

Trevi Therapeutics presently has a consensus price target of $27.08, indicating a potential upside of 81.16%. Definium Therapeutics has a consensus price target of $64.88, indicating a potential upside of 67.16%. Given Trevi Therapeutics' higher possible upside, analysts clearly believe Trevi Therapeutics is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.00

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

Summary

Trevi Therapeutics beats Definium Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Trevi Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRVI vs. The Competition

Export

Metric	Trevi Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.13B	$12.49B	$7.24B	$12.95B
Dividend Yield	N/A	2.64%	2.57%	12.80%
P/E Ratio	-43.97	797.25	275.49	25.40
Price / Sales	N/A	753.60	639.55	87.39
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	10.45	10.53	10.46	6.33
Net Income	-$42.76M	$2.82B	$3.49B	$358.33M
7 Day Performance	-5.97%	1.69%	0.59%	1.12%
1 Month Performance	-18.08%	0.24%	-1.74%	-2.39%
1 Year Performance	83.44%	3.95%	18.13%	5.35%

Trevi Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRVI Trevi Therapeutics	3.758 of 5 stars	$14.95 -1.7%	$27.08 +81.2%	+83.4%	$2.13B	N/A	N/A	34	Positive News Insider Trade
BLTE Belite Bio	3.6878 of 5 stars	$168.75 -0.4%	$218.73 +29.6%	+143.5%	$6.80B	N/A	N/A	41
LNTH Lantheus	3.9366 of 5 stars	$100.80 +0.1%	$108.11 +7.3%	+99.5%	$6.58B	$1.54B	24.35	1,193
LQDA Liquidia	3.9257 of 5 stars	$69.62 +5.9%	$98.08 +40.9%	+181.2%	$6.23B	$158.32M	50.82	216	Analyst Upgrade Insider Trade
AMRX Amneal Pharmaceuticals	3.379 of 5 stars	$17.88 +7.4%	$19.57 +9.5%	+90.7%	$5.71B	$3.02B	36.48	8,500	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRVI) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trevi Therapeutics (TRVI) Competitors

TRVI vs. BLTE, LNTH, LQDA, AMRX, and DFTX

How does Trevi Therapeutics compare to Belite Bio?

Summary

How does Trevi Therapeutics compare to Lantheus?

Summary

How does Trevi Therapeutics compare to Liquidia?

Summary

How does Trevi Therapeutics compare to Amneal Pharmaceuticals?

Summary

How does Trevi Therapeutics compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVI vs. The Competition

Trevi Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trevi Therapeutics (TRVI) Competitors

TRVI vs. BLTE, LNTH, LQDA, AMRX, and DFTX

How does Trevi Therapeutics compare to Belite Bio?

Is TRVI or BLTE more profitable?

Do analysts rate TRVI or BLTE?

Which has stronger earnings and valuation, TRVI or BLTE?

Do institutionals and insiders hold more shares of TRVI or BLTE?

Which has more risk and volatility, TRVI or BLTE?

Does the media favor TRVI or BLTE?

Summary

How does Trevi Therapeutics compare to Lantheus?

Do analysts prefer TRVI or LNTH?

Which has better valuation & earnings, TRVI or LNTH?

Is TRVI or LNTH more profitable?

Which has more risk and volatility, TRVI or LNTH?

Does the media favor TRVI or LNTH?

Do insiders and institutionals have more ownership in TRVI or LNTH?

Summary

How does Trevi Therapeutics compare to Liquidia?

Do analysts rate LQDA or TRVI?

Do institutionals and insiders believe in LQDA or TRVI?

Which has preferable valuation and earnings, LQDA or TRVI?

Does the media refer more to LQDA or TRVI?

Which has more risk and volatility, LQDA or TRVI?

Is LQDA or TRVI more profitable?

Summary

How does Trevi Therapeutics compare to Amneal Pharmaceuticals?

Does the media favor TRVI or AMRX?

Do analysts recommend TRVI or AMRX?

Which has more volatility and risk, TRVI or AMRX?

Do insiders and institutionals believe in TRVI or AMRX?

Which has preferable earnings & valuation, TRVI or AMRX?

Is TRVI or AMRX more profitable?

Summary

How does Trevi Therapeutics compare to Definium Therapeutics?

Which has more risk & volatility, TRVI or DFTX?

Does the media favor TRVI or DFTX?

Do insiders and institutionals hold more shares of TRVI or DFTX?

Is TRVI or DFTX more profitable?

Do analysts prefer TRVI or DFTX?

Which has stronger earnings & valuation, TRVI or DFTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVI vs. The Competition

Trevi Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools